Top 3 Picks
2026 Outlook
The Medical Labs sector is poised for robust growth through 2026, fueled by trends like the adoption of precision medicine and digital health integration, with the global market expected to reach $300 billion annually. Key drivers include increasing demand for early disease detection and regulatory approvals for advanced testing, potentially achieving a CAGR of 6-8%. However, investors should monitor risks such as supply chain disruptions and evolving reimbursement policies that could impact profitability.
Complete Rankings
| Rank | Stock | Score | Price | Market Cap |
|---|---|---|---|---|
|
1
|
BioNexus Gene Lab Corp Common stock
|
65.0 | $3.94 | $10M |
|
2
|
American Shared Hospital Services
|
63.3 | $2.10 | $16M |
|
3
|
Labcorp Holdings Inc.
|
60.9 | $251.66 | $23.2B |
|
4
|
Celcuity Inc. Common Stock
|
60.8 | $100.55 | $1.9B |
|
5
|
Fulgent Genetics, Inc. Common Stock
|
59.5 | $25.59 | $719M |
|
6
|
Veracyte, Inc.
|
58.2 | $42.39 | $2.8B |
|
7
|
Biodesix, Inc. Common Stock
|
57.9 | $6.46 | $61M |
|
8
|
RadNet, Inc. Common Stock
|
57.3 | $70.95 | $6.0B |
|
9
|
GRAIL, Inc. Common Stock
|
56.9 | $88.87 | $2.2B |
|
10
|
Sera Prognostics, Inc. Class A Common Stock
|
55.8 | $3.00 | $112M |
|
11
|
Natera, Inc. Common Stock
|
55.6 | $228.84 | $22.2B |
|
12
|
Caris Life Sciences, Inc. Common Stock
|
54.6 | $26.98 | $8.5B |
|
13
|
Exagen Inc. Common Stock
|
54.6 | $6.04 | $242M |
|
14
|
Guardant Health, Inc. Common Stock
|
54.0 | $101.74 | $7.8B |
|
15
|
Quest Diagnostics Inc.
|
53.8 | $173.79 | $20.4B |
In-Depth Analysis: Top Medical Labs Stocks
BGLC
BioNexus Gene Lab Corp, through its wholly owned subsidiary, focuses on the sale of chemical raw materials for the manufacture of industrial, medical, appliance, aero, automotive, mechanical, and electronic industries in the Southeast Asia region. These countries include Malaysia, Indonesia, Vietnam, and other countries in Southeast Asia. In addition, the Company is in the business of developing and providing safe, …
BioNexus Gene Lab Corp matters in the Medical Labs sector as it supplies essential chemical raw materials for medical manufacturing in Southeast Asia, supporting industries in rapidly growing markets like Malaysia, Indonesia, and Vietnam. Its Tradestie Score of 65.0/100 highlights moderate market appeal amid regional healthcare expansion.
The company's negative profit margin of -24.3% and ROE of -28.3% indicate significant operational inefficiencies and poor returns on equity, signaling challenges in financial health. Coupled with a revenue growth decline of -3.3%, this suggests ongoing struggles to achieve profitability in a competitive sector.
By 2026, investors should consider BGLC due to the projected growth in Southeast Asia's healthcare sector, where increasing demand for medical supplies could drive recovery in regions like Malaysia and Indonesia. The company's established supply chain for medical raw materials positions it to capitalize on emerging opportunities in medical technology and post-pandemic recovery. Additionally, a Tradestie Score of 65.0/100 suggests potential for valuation improvement if operational efficiencies are achieved.
AMS
American Shared Hospital Services provides stereotactic radiosurgery equipment, Advanced radiation therapy, and related equipment. It currently provides Gamma Knife units to medical centers and stand-alone facilities. The company, along with its subsidiaries, operates through the following operations: Gamma Knife, Advanced Radiation Therapy Equipment and Services, and Proton Beam Radiation Therapy Operations. It generates most of its revenue from the domestic …
American Shared Hospital Services matters in the Medical Labs sector as a specialized provider of Gamma Knife units and advanced radiation therapy equipment, addressing critical needs in stereotactic radiosurgery for cancer treatment and enhancing precision in medical procedures.
With a profit margin of -7.6% and a return on equity of -11.9%, American Shared Hospital Services is currently unprofitable and struggling with equity efficiency, highlighting financial challenges despite a modest revenue growth of 2.5% and a Tradestie Score of 63.3/100 that suggests moderate operational stability.
The company's 2.5% revenue growth indicates potential for scaling in the expanding medical labs sector, particularly with increasing demand for advanced radiation therapy equipment by 2026. Its focus on Gamma Knife units positions it to benefit from rising cancer treatment volumes, potentially improving profitability as healthcare technologies advance. Additionally, the Tradestie Score of 63.3/100 reflects a baseline for growth, making it an opportunistic buy for investors anticipating sector recovery.
LH
Labcorp is one of the nation's two largest independent clinical laboratories, with roughly 20% of the independent lab market. The company operates approximately 2,000 patient-service centers, offering a broad range of 5,000 clinical lab tests, ranging from routine blood and urine screens to complex oncology and genomic testing.
Labcorp Holdings Inc. is a leading force in the Medical Labs sector, commanding approximately 20% of the independent lab market and operating around 2,000 patient-service centers, which underscores its scale and accessibility in providing essential diagnostic services.
Labcorp's profit margin of 6.2% indicates moderate efficiency in converting revenue to profit, while its ROE of 10.1% reflects solid returns on equity, supported by an 8.6% revenue growth that signals financial stability despite a P/E ratio of 24.8 suggesting a growth-oriented valuation.
Labcorp's 8.6% revenue growth highlights its ability to capitalize on increasing demand for clinical lab services, driven by an aging population and expanding healthcare needs, making it an attractive investment by 2026. The company's dominant market position with over 5,000 tests and a Tradestie Score of 60.9 indicate potential for sustained profitability and market share gains amid sector innovations. Furthermore, its operational scale could benefit from regulatory advancements and digital health integrations, enhancing long-term shareholder value.
CELC
Celcuity Inc is a clinical-stage biotechnology company pursuing development for oncology. The Company's lead therapeutic candidate is gedatolisib, a potent pan-PI3K and mTOR inhibitor. Its mechanism of action and pharmacokinetic properties are differentiated from other currently approved and investigational therapies that target PI3K or mTOR alone or together. A Phase 3 clinical trial, VIKTORIA-1, evaluating gedatolisib in combination with fulvestrant …
Celcuity Inc. matters in the Medical Labs sector as a clinical-stage biotechnology company developing innovative oncology treatments, with gedatolisib standing out as a potent pan-PI3K and mTOR inhibitor that differentiates through its unique mechanism of action and pharmacokinetic properties compared to approved therapies. This positions the company to address unmet needs in cancer care, potentially transforming personalized medicine within the sector.
Celcuity's ROE of -122.0% highlights severe profitability challenges, indicating substantial losses relative to equity as the company invests heavily in clinical development, which is typical for early-stage biotechs. The Tradestie Score of 60.8/100 suggests moderate financial appeal, reflecting a balance between high-risk operations and potential future upside from their pipeline.
By 2026, investors should consider CELC due to the potential advancement of gedatolisib through clinical trials, which could lead to FDA approval and significant revenue from oncology markets. The drug's differentiated profile may secure a competitive edge in treating cancers with PI3K/mTOR pathway involvement, driving stock value amid growing demand for targeted therapies. Additionally, if Celcuity achieves key milestones, such as positive trial results, the company's valuation could appreciate substantially in a expanding biotech landscape.
FLGT
Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in laboratory services business and a therapeutic development business. The laboratory services business which generates key revenue includes, technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused …
Fulgent Genetics matters in the Medical Labs sector due to its specialization in genetic testing, which delivers clinically actionable diagnostic information to physicians, enhancing personalized medicine and therapeutic development. Its dual focus on laboratory services and therapeutic development positions it as a key player in advancing genomic diagnostics amid growing demand for precision healthcare.
Fulgent Genetics exhibits weak profitability with a -13.6% profit margin and -3.9% ROE, indicating current losses and inefficient use of equity; however, its 17.2% revenue growth reflects strong business expansion, suggesting potential for improved financial health if cost management improves.
With 17.2% revenue growth driven by increasing demand for genetic testing, Fulgent Genetics is well-positioned for market expansion by 2026 as personalized medicine advances. The company's Tradestie Score of 59.5/100 indicates moderate investment appeal, potentially improving with ongoing therapeutic developments that could enhance profitability. Investors should consider buying due to the sector's projected growth, where genetic diagnostics are expected to play a pivotal role in healthcare innovations by 2026.
VCYT
Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder). In addition, its Percepta Nasal Swab test is being run …
Veracyte Inc. matters in the Medical Labs sector due to its specialized genomic diagnostics, such as Decipher for prostate cancer, Afirma for thyroid cancer, and Prosigna for breast cancer, which provide clinicians with precise tools to diagnose and personalize cancer treatment. This innovation positions the company as a leader in advancing precision medicine, addressing critical gaps in early cancer detection and improving patient outcomes.
Veracyte's profit margin of 6.1% indicates moderate profitability, reflecting the company's ability to generate earnings amid R&D investments in genomics. However, a low ROE of 2.5% suggests inefficient use of equity, though the 13.8% revenue growth demonstrates strong financial health and potential for scaling operations despite a high P/E ratio of 111.3 signaling high market expectations.
Veracyte's 13.8% revenue growth highlights its expanding market presence in cancer diagnostics, driven by increasing demand for personalized medicine that could accelerate by 2026 with advancements in genomics. The company's diverse test portfolio, including key offerings for prostate, thyroid, and breast cancer, positions it to capture greater market share as healthcare systems prioritize early detection. Additionally, with a Tradestie Score of 58.2 indicating moderate investment appeal, Veracyte offers upside potential for investors betting on the sector's growth trajectory toward 2026.
BDSX
Biodesix Inc is a diagnostic solutions company with a focus in lung disease. The Company has a single operating segment focused on providing diagnostic testing services to customers. It provides biopharmaceutical companies with services that include diagnostic research, clinical trial testing, and the discovery, development, and commercialization of companion diagnostics. The revenue is derived from two sources, providing diagnostic testing …
Biodesix matters in the Medical Labs sector as a specialized provider of diagnostic testing for lung diseases, addressing a critical need in an era of rising respiratory health challenges. Its services to biopharmaceutical companies, including diagnostic research and clinical trial testing, enhance drug development pipelines and support innovative treatments.
Biodesix's profitability is challenged by a -49.3% profit margin and a -302.6% ROE, indicating significant losses and inefficient use of equity, which highlights financial strain despite operations in a growing sector. However, the company's 19.9% revenue growth suggests potential for improvement as it scales its diagnostic services and partnerships.
Biodesix's 19.9% revenue growth positions it for continued expansion in the lung disease diagnostics market, driven by increasing demand for personalized medicine and clinical trial services by 2026. The Tradestie Score of 57.9/100 indicates moderate investment appeal, with opportunities for profitability turnaround through operational efficiencies and strategic partnerships. As the Medical Labs sector evolves, Biodesix's focus on lung diagnostics could yield higher valuations if revenue trends persist and losses narrow.
RDNT
RadNet Inc is a national provider of diagnostic imaging services that operates in two business segments: Imaging Center segment and Digital Health segment. The Imaging Center segment provides physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders. Services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, mammography, ultrasound, diagnostic …
RadNet Inc. matters in the Medical Labs sector as a leading national provider of diagnostic imaging services, operating through its Imaging Center segment for disease diagnosis and treatment, and its Digital Health segment for innovative healthcare solutions. This dual-segment approach positions the company to capitalize on the growing demand for advanced imaging amid an aging population and increasing healthcare digitization.
RadNet's negative profit margin of -0.6% indicates current operational losses, potentially due to high costs in expanding services, while its low ROE of 1.8% suggests inefficient use of shareholder equity. However, the company's strong revenue growth of 13.4% reflects robust business expansion, which could improve financial health if profitability margins are optimized through cost management and segment synergies.
With RadNet's revenue growth at 13.4%, driven by its expanding Imaging Center and Digital Health segments, the company is well-positioned for increased demand in diagnostic services by 2026, potentially leading to profitability turnaround. The moderate Tradestie Score of 57.3/100 indicates room for upside in operational efficiency, supported by trends in telemedicine and AI-enhanced imaging. Investors should consider RDNT for its growth potential in a sector expected to expand with healthcare innovations, offering opportunities for stock appreciation as the company scales and improves margins.
GRAL
GRAIL Inc is a healthcare company focused on developing technologies for early cancer detection. The company has developed a multi-cancer early detection blood test that has the ability to detect all types of cancer, across all stages. It operates in one reportable operating segment which provides multi-cancer early detection testing and service.
GRAIL Inc. matters in the Medical Labs sector due to its pioneering multi-cancer early detection blood test, which can identify over 50 types of cancer across all stages, potentially transforming preventive healthcare. This innovation addresses a critical unmet need in oncology, enhancing early intervention and improving survival rates in a growing market projected to exceed $10 billion by 2026.
GRAIL's profitability is severely strained, evidenced by a -286.4% profit margin that highlights substantial operational losses relative to revenue, alongside a -16.8% ROE indicating inefficient use of shareholders' equity. However, the company's 26.3% revenue growth demonstrates promising expansion potential, which could alleviate financial pressures if scaled effectively.
By 2026, GRAIL's 26.3% revenue growth trajectory suggests accelerating market adoption of its multi-cancer detection technology, potentially driven by increasing demand for non-invasive diagnostics amid rising cancer incidence rates. The company's focus on early-stage detection could lead to strategic partnerships and regulatory approvals, enhancing its competitive edge in the Medical Labs sector. With a Tradestie Score of 56.9 indicating moderate appeal, investors may see upside as GRAIL advances toward profitability through expanded clinical applications and broader commercialization efforts.
SERA
Sera Prognostics Inc is a health diagnostic company. It develops diagnostic tests for the early prediction of a woman's individualized risk of premature birth, preeclampsia, gestational diabetes, stillbirth, and other conditions. The proprietary proteomics and bioinformatics platform of the company helps to improve maternal and neonatal health by discovering, developing, and commercializing blood-based biomarker tests, and predictive analytic products and …
Sera Prognostics matters in the Medical Labs sector because its proprietary proteomics and bioinformatics platform enables early prediction of pregnancy complications like premature birth and preeclampsia, addressing a critical gap in women's health and potentially reducing healthcare costs through personalized diagnostics. This innovation positions the company as a key player in the growing market for predictive health tests, where demand for non-invasive, data-driven solutions is increasing.
Sera Prognostics exhibits poor profitability with a Return on Equity (ROE) of -47.7%, indicating that the company is not generating returns on shareholders' investments and is likely relying on external funding to sustain operations. Additionally, the -44.8% revenue growth reflects significant challenges in sales and market penetration, underscoring financial instability in the competitive Medical Labs landscape.
Investors should consider buying SERA stock in 2026 due to the projected expansion of the prenatal diagnostics market, expected to grow as personalized medicine advances, potentially boosting demand for Sera's predictive tests and leading to revenue recovery. With a Tradestie Score of 55.8 suggesting moderate upside potential, the company's innovative platform could gain traction through possible FDA approvals or partnerships, positioning it for market share gains. Furthermore, if Sera overcomes current financial hurdles, its focus on high-impact women's health issues could drive long-term valuation growth as healthcare providers prioritize early intervention strategies.
Methodology
Stocks are ranked using the Tradestie Score, a proprietary 0-100 rating that combines fundamental quality (profitability, balance sheet strength), growth metrics (revenue and earnings growth), valuation (P/E, PEG ratio), and momentum factors. Scores are updated daily based on the latest market data. Learn more about our methodology.